LACTOLOGY FOUNDATION

Olsalazine (ATC A07EC03)

ATC class and general pharmacology

Olsalazine (sodium azodisalicylate; azodisal sodium) is classified under ATC code A07EC03, situated within the alimentary tract and metabolism group (A), antidiarrheals, intestinal anti-inflammatory/anti-infective agents (A07), intestinal anti-inflammatory agents (A07E), and the aminosalicylic acid and similar agents subclass (A07EC), alongside sulfasalazine (A07EC01), mesalazine (A07EC02), and balsalazide (A07EC04). Marketed as Dipentum, olsalazine is chemically distinctive within the aminosalicylate class in that it is composed of two molecules of 5-aminosalicylic acid (5-ASA, mesalamine) joined by a single azo bond, functioning as a symmetric homodimeric prodrug rather than incorporating a heterologous carrier such as sulfapyridine (DrugBank; ScienceDirect Topics).pubchem.ncbi.nlm.nih+2

Following oral administration, olsalazine exhibits markedly limited systemic bioavailability: pharmacokinetic studies based on oral and intravenous dosing indicate that only approximately 2.4–5% of a single dose is absorbed intact, with less than 1% recovered unchanged in urine. The remaining 95–99% of the administered dose reaches the colon intact, where colonic bacterial azoreductases and the low prevailing redox potential of the colonic lumen rapidly cleave the azo bond, liberating two molecules of 5-ASA per molecule of olsalazine — thereby delivering approximately twice the quantity of active moiety to the colonic mucosa, on a weight basis, compared with an equivalent dose of sulfasalazine, and without any residual carrier molecule analogous to sulfapyridine (FDA label — DIPENTUM; Health Canada product monograph). Maximum serum concentrations of intact olsalazine appear at approximately 1 hour post-dose and remain low even after a 1 g single dose (1.6–6.2 μmol/L), with a short systemic elimination half-life of approximately 0.9 hours; the minor sulfated metabolite olsalazine-O-sulfate, by contrast, has a considerably longer half-life of approximately 7 days (Drugs.com Professional Monograph; FDA label — DIPENTUM).accessdata.fda+2

The precise anti-inflammatory mechanism of the liberated 5-ASA moiety remains incompletely defined but is understood to be predominantly topical/local rather than systemic in nature. Proposed pathways include inhibition of cyclooxygenase and lipoxygenase enzymes, thereby reducing mucosal production of prostaglandins, leukotrienes (notably leukotriene B4), and hydroxyeicosatetraenoic acids (HETEs) from arachidonic acid; free-radical scavenging via inhibition of xanthine oxidase; suppression of in vitro intestinal macrophage migration in response to leukotriene B4; and inhibition of ileal and colonic Na⁺/K⁺-ATPase (DrugBank; Health Canada product monograph). Notably, olsalazine itself — independent of its 5-ASA metabolite — increases net luminal water and electrolyte secretion and accelerates intestinal transit, an intrinsic pharmacodynamic property distinct from the anti-inflammatory action of its liberated moiety, and one with direct clinical toxicological consequences discussed below (PubMed — pharmacodynamic/pharmacokinetic review; ScienceDirect Topics).pubmed.ncbi.nlm.nih+3

Clinically, olsalazine is indicated specifically for maintenance of remission of ulcerative colitis in adult patients who are intolerant of sulfasalazine, reflecting its historical development as a sulfapyridine-free alternative rather than a first-line agent (FDA label — DIPENTUM; MedlinePlus). Standard adult dosing is 500 mg twice daily (1 g/day total), typically administered after meals to reduce gastrointestinal intolerance. Clinical experience indicates that fewer than 14% of patients who were allergic or intolerant to sulfasalazine experienced similar hypersensitivity-type reactions to olsalazine, supporting its role as a substitute agent in this population.medlineplus+3

Toxicological profile

The single most characteristic and clinically significant toxicological feature of olsalazine — distinguishing it from other aminosalicylates — is a high incidence of dose-related, self-limited diarrhoea attributable to the intact prodrug molecule itself rather than to its 5-ASA metabolite. Across clinical trial data, approximately 17% of olsalazine-treated patients (versus 6.7% on placebo) reported diarrhoea during therapy, with discontinuation required in roughly 6% of cases; abdominal pain/cramps (10.1% versus 7.2% placebo) and nausea (5.0%) were also reported at rates exceeding placebo (FDA label — DIPENTUM; Health Canada product monograph). This diarrhoea typically manifests within the first week of initiating treatment or following a dosage increase, is distinguishable from an ulcerative colitis flare by its high water content and characteristic absence of blood, and is mechanistically explained by olsalazine's direct inhibition of intestinal sodium, chloride, and potassium absorption, converting normal absorptive flux into net secretion across small intestinal and colonic segments — an effect that does not diminish with mucosal adaptation even after a month of chronic administration (PubMed — rat intestinal adaptation study; Drugs.com Professional Monograph). Dosage reduction, more frequent dosing intervals, gradual titration, and administration with food generally mitigate severity, and symptoms often resolve without dose adjustment and without subsequent recurrence (Drugs.com Professional Monograph; ScienceDirect Topics).pubmed.ncbi.nlm.nih+4

As with other 5-ASA-releasing agents, olsalazine can precipitate a mesalamine-induced acute intolerance syndrome, clinically difficult to distinguish from an ulcerative colitis exacerbation, characterised by cramping, acute abdominal pain, bloody diarrhoea, fever, headache, and rash, and requiring prompt drug withdrawal upon suspicion (FDA label — DIPENTUM; Mayo Clinic).mayoclinic+1

Preclinical toxicology identifies the kidney as the principal target organ of olsalazine toxicity. In subacute and chronic rat toxicity studies, oral doses of 400 mg/kg/day or higher produced nephritis and tubular necrosis after four weeks, interstitial nephritis and tubular calcinosis after six months, and renal fibrosis and mineralisation with more prolonged exposure (FDA label — DIPENTUM; Health Canada product monograph — DIPENTUM (2009 label)). While clinical human renal toxicity signals for olsalazine specifically are comparatively less extensively documented than for mesalazine, prescribing information nonetheless warns of serious kidney effects, including kidney stones and decreased urine output, warranting prompt medical evaluation of any new lower back/side pain, haematuria, oliguria, or unexplained oedema.accessdata.fda+2

Acute toxicity is low: maximum single oral doses of 5 g/kg in mice and rats and 2 g/kg in dogs were not lethal, with acute toxic signs limited to decreased motor activity, diarrhoea, and vomiting (dogs). No human overdose fatalities have been reported, and clinical experience with human overdose remains limited; as an aminosalicylate/salicylate derivative, overdose symptoms are expected to mirror classic salicylate toxicity — nausea, vomiting, abdominal pain, tachypnoea, hyperpnoea, tinnitus, and neurologic symptoms including headache, dizziness, confusion, and seizures — with severe intoxication potentially producing electrolyte and acid-base disturbance and secondary organ (renal, hepatic) damage. No specific antidote exists; management is supportive, including gastrointestinal decontamination, correction of fluid and electrolyte imbalance, and maintenance of adequate renal function (DrugBank; FDA label — DIPENTUM).accessdata.fda+2

Additional documented adverse effects include severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms [DRESS], and acute generalised exanthematous pustulosis), hepatic enzyme elevation, rash (approximately 2.3% of patients), arthralgia/joint pain (approximately 4%), depression, insomnia, dizziness, headache, and upper respiratory infection (Mayo Clinic; Drugs.com Side Effects; MedicineNet). Olsalazine may also cause harmless reddish-brown urine discoloration on contact with surfaces such as toilet water.medlineplus+3

Lactation pharmacology and infant exposure

Olsalazine demonstrates exceptionally limited transfer into human milk, more restricted than that observed for either sulfasalazine or mesalazine. In a dedicated pharmacokinetic study, olsalazine and its metabolites — olsalazine sulfate and mesalamine — were undetectable (below the assay limit of 170 μg/L) in breast milk at all sampled time points from 30 minutes to 48 hours after a maternal dose. The inactive metabolite N-acetyl-5-ASA was detectable only at 10, 14, and 24 hours post-dose, at low concentrations of 170, 183, and 264 μg/L respectively — corresponding to a relative infant dose not exceeding 1% (LactMed/NCBI Bookshelf; e-lactation). Spanish-language pharmacokinetic reference data similarly report a theoretical infant dose of approximately 0.06 mg/kg/day, corresponding to a relative infant dose of only 0.4% of the maternal weight-adjusted dose — substantially below the conventional 10% threshold of clinical concern.ncbi.nlm.nih+2

Direct clinical observation data, although limited in volume, are reassuring. One infant breastfed throughout maternal olsalazine therapy for Crohn's disease showed no rash, wheezing, vomiting, or diarrhoea after 2 and 3 weeks of exposure. A separately documented infant exposed to maternal olsalazine likewise presented no clinical problems. The principal theoretical concern for aminosalicylate-exposed infants generally — diarrhoea attributable to the active 5-ASA moiety — has been documented predominantly with other mesalamine-releasing preparations rather than specifically with olsalazine; a broader case-control study comparing 121 infants exposed via milk to mesalamine, olsalazine (n = 2), or sulfasalazine (n = 2) against 121 unexposed matched controls found no significant difference in the frequency or nature of maternally reported adverse events over an average follow-up of approximately 22 months (LactMed/NCBI Bookshelf; e-lactation).ncbi.nlm.nih+2

Because olsalazine's own diarrhoeagenic mechanism (direct inhibition of intestinal ion absorption) operates locally within the maternal gastrointestinal tract prior to colonic bioconversion, and because systemic maternal absorption of intact olsalazine is minimal (2.4–5%), there is no established pharmacological basis for olsalazine's characteristic maternal diarrhoea-inducing property to translate into a distinct infant risk beyond the generic 5-ASA-related diarrhoea risk shared across the aminosalicylate class (FDA label — DIPENTUM; e-lactancia.org). No sulfonamide-related risks (haemolysis, bilirubin displacement) apply to olsalazine, as it — like mesalazine — is entirely free of a sulfapyridine carrier.accessdata.fda+2

Lactological safety assessment and clinical recommendations

Olsalazine is classified by independent lactation-risk reference systems (e-lactancia/e-lactation) at the lowest risk category — "very low risk," compatible with breastfeeding and not considered a risk to the infant — with expert consensus (Torres 2023, Russell 2023, Nguyen 2016, McConnell 2016, Mahadevan 2015, van der Woude 2015, Nielsen 2014) supporting the general compatibility of mesalamine and its prodrugs, including olsalazine, during lactation (e-lactancia.org; e-lactation). No specific pharmacological alternative is proposed by these references, reflecting the assessment that olsalazine's lactation risk profile is already favourable.e-lactancia+1

Based on the convergent pharmacokinetic and clinical-outcome evidence, the following lactological safety assessment and clinical recommendations are proposed:

• Overall risk categorisation: Very low risk to the term, healthy breastfed infant. The essentially undetectable transfer of intact olsalazine and mesalamine into milk, together with a relative infant dose for the inactive N-acetyl-5-ASA metabolite of under 1%, represents one of the most favourable pharmacokinetic profiles among the aminosalicylate class for lactational exposure (LactMed/NCBI Bookshelf; e-lactancia.org).ncbi.nlm.nih+1
• Continuation of breastfeeding: Maternal olsalazine therapy is not, on current evidence, a reason to discontinue breastfeeding; mothers requiring olsalazine for maintenance of ulcerative colitis remission should be supported to continue nursing while receiving the medication.ncbi.nlm.nih
• Infant clinical monitoring: Breastfed infants should nonetheless be observed for diarrhoea, given that this remains a documented (if infrequent) adverse effect across the broader aminosalicylate class in breastfed infants; any onset of diarrhoea, rash, or feeding intolerance in the infant should prompt clinical evaluation.ncbi.nlm.nih
• Distinguishing maternal versus infant effects: Because olsalazine itself frequently causes diarrhoea in the treated mother via a distinct, non-immunologic secretory mechanism, clinicians should differentiate maternal drug-induced diarrhoea from any gastrointestinal symptom reported in the infant, as the pharmacokinetic data do not support a mechanistic link between maternal olsalazine-induced diarrhoea and infant gastrointestinal symptoms via milk transfer (PubMed — rat intestinal adaptation study; FDA label — DIPENTUM).pubmed.ncbi.nlm.nih+1
• Preference within the aminosalicylate class: For lactating patients requiring an aminosalicylate who are intolerant of sulfasalazine, olsalazine represents a pharmacologically favourable option given its documented near-absence of transfer into milk; however, choice between olsalazine and mesalazine during lactation should be guided primarily by maternal gastrointestinal tolerability (given olsalazine's higher intrinsic diarrhoea incidence), rather than by lactation safety considerations alone, since both agents show comparably reassuring infant-exposure data (Health Canada product monograph; e-lactation).pdf.hres+1
• Maternal monitoring independent of lactation status: Given the preclinical nephrotoxic signal associated with olsalazine, periodic assessment of maternal renal function is prudent during lactation, consistent with general aminosalicylate-class monitoring recommendations, irrespective of breastfeeding status.accessdata.fda
• Dose considerations: No lactation-specific dose adjustment has been established; the standard maintenance dose (typically 500 mg twice daily) should be used as clinically indicated, since milk transfer at standard doses is already minimal and dose-proportionality data specific to lactational transfer are not established (Mayo Clinic; e-lactancia.org).mayoclinic+1

In summary, olsalazine's pharmacokinetic profile — characterised by minimal systemic maternal absorption and near-undetectable transfer of the active moiety into breast milk — together with limited but reassuring direct clinical observation data, supports its classification as compatible with breastfeeding, with routine infant monitoring for gastrointestinal symptoms recommended as a general precaution applicable across the aminosalicylate drug class.